Clinical effect of dipyridamole in patients with IgA nephropathy.
Clinical effects of dipyridamole and carbazochrome sodium sulfonate in patients with IgA nephropathy are described. Oral administration of 300 mg of dipyridamole and 180 mg of carbazochrome sodium sulfonate per day was employed in the present study. Urinalysis and renal function tests, i.e. serum creatinine (s-Cr), blood urea nitrogen (BUN), glomerular filtration rate (GFR) and phenolsulfonphtalein (PSP) tests, were performed before and after the administration of dipyridamole. It was demonstrated that the administration of dipyridamole was effective in reducing the level of proteinuria in the patients. The administration of carbazochrome sodium sulfonate was not effective in reducing the proteinuria level. It was concluded that the administration of dipyridamole may be useful for treatment of patients with IgA nephropathy.
D000323:Adrenochrome / Q000031:analogs & derivatives / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy; D005922:Glomerulonephritis, IGA / Q000188:drug therapy*; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D011507:Proteinuria / Q000188:drug therapy
D004176:Dipyridamole; D000323:Adrenochrome; C073338:carbazochrome